Overview of EHA's Hemoglobinopathies Initiatives

The EHA Topics-in-Focus Hemoglobinopathies Program  (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.

EHA Grants Hall of Fame

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

EHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!

Live days: April 29-30, 2021

Content available: April 22, 2021 – May 29, 2021

Chair: Prof Dr C Dufour

Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: to be announced
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration will be open soon

Program The EHA-SWG scientific meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid…

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

EU funding crucial in allowing medical researchers across member states to collaborate in the development of new treatments

In an article published in Science|Business, Prof.

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.